破發!雲康集團(2325.HK)首日上市半日收跌4.82%
格隆匯5月18日丨醫學營運服務商雲康集團(2325.HK)今日首日在港上市,盤中一度跌超16%至6.6港元,截至半日收盤跌4.82%報7.51港元,成交1.32億港元,市值46億港元。雲康集團發售價為每股7.89元,集資淨額7.6億元,一手中籤率100%。公司指所得款項淨額的55%將用於未來四年擴大並深化其醫聯體網絡,20%於未來三年內分配用於升級並提升其醫學運營服務提供商的營運能力,10%用於擴大其診斷能力及豐富診斷檢測組合,5%用於尋找潛在投資及收購機會,5%用於招聘及培訓人才庫,5%用作營運資金及一般企業用途。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.